Introduction {#sec1}
============

Intestinal failure (IF) can be defined as a reduction in gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth, usually as parenteral nutrition (PN) for more than 2 mo ([@bib1]--[@bib3]). The etiology of IF includes a range of conditions, such as short bowel syndrome (SBS) and motility disorders ([@bib4]). SBS is frequently the result of extensive intestinal resection for congenital (e.g., gastroschisis) or acquired \[e.g., necrotizing enterocolitis (NEC) ([@bib5])\] disorders.

Despite the wide range of underlying pathology leading to IF and the requirement of complex medical management approaches, there are a number of common challenges which have been identified as being linked to medium- and long-term outcomes, for example catheter-related sepsis ([@bib4]). Furthermore, a number of novel treatment strategies have been developed since the introduction of PN half a century ago ([@bib6], [@bib7]). Among these are the establishment of specialist intestinal rehabilitation centers ([@bib8]), use of omega-3-polyunsaturated lipid in PN ([@bib9]), and refinement of intestinal lengthening surgical techniques ([@bib10]). Individual centers have reported improvements in mortality ([@bib11]) but this has yet to be systematically established.

The primary aim of managing IF in childhood is to achieve enteral autonomy by optimizing intestinal function, leading to complete independence from PN. However, in a large proportion of patients this cannot be achieved and hence avoiding complications \[such as IF-associated liver disease (IFALD)\] while providing a high quality of life for patients becomes the main priority.

Indeed, the majority of long-term adverse clinical outcomes in IF patients have been linked to prolonged requirement for PN, notably the development of IFALD and catheter-related bloodstream infections ([@bib4]). A number of other clinical \[e.g., NEC etiology ([@bib12]), small bowel length, presence of ileocecal valve (ICV)\] and biochemical \[e.g., plasma citrulline ([@bib13])\] factors have also been associated with outcomes, in particular enteral autonomy. Although some of these associations have been robustly replicated (e.g., small bowel length and enteral autonomy), others have been reported only in isolated cohorts (e.g., PN duration and development of liver failure) ([@bib14], [@bib15]).

To date, the majority of studies reporting outcomes have been single center and retrospective, though some larger multicenter studies have been conducted ([@bib3], [@bib16]--[@bib19]). However, in order to identify common parameters that are closely linked with long-term outcomes in children with IF, the analysis of larger datasets is required. Results of such analyses have the potential to provide the basis for the development of treatment guidelines, optimize clinical practice, and ultimately lead to improved outcomes.

In this study, we conducted a systematic review, meta-analysis, and meta-regression of prospective and retrospective cohort studies reporting long-term clinical outcomes of childhood-onset IF. We specifically aimed to establish the incidence of key clinical outcome measures and identify predictors that can be used to optimize treatment approaches in the future.

Subjects and Methods {#sec2}
====================

Review protocol and eligibility criteria {#sec2-1}
----------------------------------------

The study protocol was prospectively registered on the PROSPERO systematic review database (CRD42017072185) and was conducted in accordance with guidelines ([@bib20], [@bib21]). Inclusion criteria were as follows: \>10 patients with childhood-onset (\<18 y) intestinal failure, \>12 mo follow-up, and data on at least 2 clinical endpoints (mortality, intestinal transplant, IFALD, enteral autonomy, sepsis, and neurodevelopment). Included study types were as follows: randomized controlled trials (RCTs), cohort studies, case control studies, case series, systematic reviews, and meta-analyses. Participants and cohorts were defined as having intestinal failure when there was a requirement of parental nutrition (PN) for \>60 consecutive days ([@bib22]), or, if these data were not available, when defined by the authors as "intestinal failure."

Studies were excluded if it was not possible to separate data from adults from those from children, there was no detail on minimum duration of PN, or it was not possible to separate outcomes for IF from those for non-IF patients. Narrative reviews, editorials, opinions, and animal research studies were also excluded.

Information sources and search strategy {#sec2-2}
---------------------------------------

MEDLINE and EMBASE (including conference abstracts from ESPGHAN, NASPGHAN, ESPEN, and ASPEN annual meetings) were searched, with the search completed on 17 March, 2019. Terms relating to IF were combined with key terms for age and clinical outcomes (e.g., IFALD, transplant). The full search strategy can be found in the **[Supplemental Methods](#sup1){ref-type="supplementary-material"}**. In addition, the reference lists from all relevant systematic reviews and meta-analyses were reviewed. No time period for publication date was specified.

Study selection and data collection {#sec2-3}
-----------------------------------

Identified studies underwent screening followed by full text review. At screening, abstracts and titles were reviewed to exclude irrelevant studies. The full texts were then assessed for inclusion/exclusion criteria. Two reviewers (ACSP and JTW) independently performed screening and full text review, with discrepancies settled by discussion with JPM.

Two authors independently extracted data from studies. Where individual studies described multiple cohorts, data were extracted for each cohort separately. To reduce the risk of duplication of patients in the meta-analysis, studies were selected for inclusion in meta-analysis and meta-regression if their reported patient outcomes did not overlap with those of other reported cohorts. The center(s) from which patients were recruited and the years of inclusion were also compared such that only nonoverlapping cohorts were included in the meta-analysis.

Data extracted included the following: study details (e.g., number of patients in cohort, location of study); patient baseline characteristics (e.g., principle etiology of IF, gestational age, sex); interventions (medical, surgical, nutritional); details of follow-up (duration, loss to follow-up); and clinical outcomes \[e.g., mortality, IFALD, liver failure, catheter-related bloodstream infections (CRBSIs) per 1000 days of catheter use, enteral autonomy, number of central venous catheters (CVCs) used, venous thrombosis, height and weight at the start and end of follow-up, and neurodevelopmental outcomes\]. All available data were included in analyses, even if not all items were reported in each study. Missing data points resulted in studies being censored from only those analyses. The number of patients included in each analysis is reported in the results. Unless otherwise stated, liver failure was defined as the number of patients listed for liver transplant, who underwent liver transplant, or who died of liver-related causes. Sixty-eight authors were contacted for missing data, with 25 responding.

Data on reported associations (or predictors) of clinical outcomes were extracted from each included study. It was recorded whether associations had been established using a univariate or multivariate analysis.

Study heterogeneity {#sec2-4}
-------------------

Studies were found to fall into 5 groups as follows: *1*) those reporting only patients on home parenteral nutrition (HPN); *2*) children who had been referred for intestinal transplant (ITx); *3*) children with established IFALD; *4*) patients undergoing intestinal lengthening surgical procedures; and *5*) other (predominantly neonatal) cohorts with IF. These 5 groups were used for descriptive purposes only, whereas meta-analysis was performed by combining all studies in a global analysis.

Quality assessment and risk of bias (in individual studies) {#sec2-5}
-----------------------------------------------------------

Two reviewers (JTW and JPM) independently assessed risk of bias in each study by applying the Cochrane Risk of Bias in Cohort Studies tool ([@bib23]).

Statistical analysis {#sec2-6}
--------------------

Primary outcome was mortality rate (percentage mortality per year of follow-up); secondary outcomes included neurodevelopmental status, transplantation, IFALD, enteral autonomy, and sepsis.

Raw data from each study were used to generate summary measures. Means with 95% CIs were calculated for baseline characteristics (age, sex, IF etiology, gestational age, birth weight, small bowel length, number of CVCs), weighted by the number of years of patient follow-up.

For clinical outcomes (total mortality, total transplants, enteral autonomy, IFALD, and liver failure), crude proportions were calculated and then meta-analysis was performed to calculate the proportion affected per year of follow-up. IFALD cohorts (with 100% IFALD prevalence) were excluded from the assessment of IFALD prevalence. Studies were weighted by person-years follow-up with double arcsine transformation ([@bib24]). Random effects were used throughout with 95% CIs. Heterogeneity was calculated according to Cochrane\'s statistic and its related metric *I*^2^. Publication bias was assessed using funnel plots, and the Egger test was used when \>10 studies were included.

Random-effects meta-regression was performed to assess the effects of baseline cohort characteristics on each clinical outcome.

Statistical analysis was performed using STATA v14.0 for Windows (StataCorp, 2015. Stata Statistical Software: Release 14).

Results {#sec3}
=======

Study selection and characteristics {#sec3-1}
-----------------------------------

In total, 2203 articles were identified, of which 201 studies were included in the systematic review that contained 220 cohorts ([**Table 1**](#tbl1){ref-type="table"}, and **[Supplemental Tables 1](#sup1){ref-type="supplementary-material"}** and **[2](#sup1){ref-type="supplementary-material"}**). After exclusion of overlapping cohorts, 175/220 cohorts (9318 patients and 34,549 patient-years follow-up) were included in the meta-analysis (**Supplemental Figure 1**). The majority of cohorts (189/220, 86%) were retrospective and most studies (161/201, 80%) were low or very-low risk of bias (**[Supplemental Figure 2](#sup1){ref-type="supplementary-material"}**).

###### 

Clinical outcomes (from meta-analysis) for patients with IF^[1](#tb1fn1){ref-type="table-fn"}^

                                        Overall (*n* = 9318)
  ------------------------------------- ----------------------
  Mean follow-up, mo                    44.5
  Total mortality, % (*n*/total)        16.5 (1377/8340)
   Weighted, %/y (95% CI)               5.2 (4.3, 6.0)
  IFALD, % (*n*/total)                  43.5 (2065/4746)
   Weighted, %/y (95% CI)               17 (14, 20)
  Liver failure, % (*n*/total)          13.9 (884/6338)
   Weighted, %/y (95% CI)               4.3 (3.4, 5.3)
  Transplant, % (*n*/total)             8.9 (731/8172)
   Weighted, %/y (95% CI)               1.2 (0.7, 1.7)
  Enteral autonomy, % (*n*/total)       54.1 (3653/6747)
   Weighted, %/y (95% CI)               20 (18, 23)
  Thrombosis, % (*n*/total)             25.7 (328/1277)
   Weighted, %/y (95% CI)               7.5 (4.3, 11.3)
  CRBSI, per 1000 catheter d (95% CI)   3.3 (3.2, 3.4)

CRBSI, catheter-related bloodstream infection; IF, intestinal failure. IFALD, IF-associated liver disease. Meta-analysis of clinical outcomes in IF for all included studies. Data were analyzed by crude proportions (*n*/total) and random effects meta-analysis for event rates (%/y).

Mortality {#sec3-2}
---------

The overall mortality of childhood IF was 5.2% per y (95% CI: 4.3, 6.0), or 16.5% (1377/8340) over a mean 44.5-mo follow-up (**[Supplemental Figure 3](#sup1){ref-type="supplementary-material"}**). The main causes of death were liver disease (23%), sepsis (18%), and posttransplant status (12%), with cause of death unknown in 35% of cases.

Rates of CRBSI ([**Figure 1**](#fig1){ref-type="fig"}) and IFALD (**[Supplemental Figure 4](#sup1){ref-type="supplementary-material"}**) were the 2 determining factors associated with mortality (**[Supplemental Table 3](#sup1){ref-type="supplementary-material"}**). Duration of PN, small bowel length, and etiology were not predictive of mortality, despite previously reported associations (**[Supplemental Figure 5](#sup1){ref-type="supplementary-material"}**).

![Meta-regression between rate of CRBSI per 1000 days and mortality per year. Each study (*n* = 53) is represented by a circle and size demonstrates weighting of each study, where larger circles indicate more patient-years of follow-up. The line of best fit shows the change in mortality rate for each incidence of CRBSI per 1000 days (β: 0.007; 95% CI: 0.003, 0.01), *P* value = 0.003. CRBSI, catheter-related bloodstream infection.](nqz110fig1){#fig1}

There was a trend of improving mortality with time: the year follow-up ended (i.e., more recent cohorts) was associated with improved mortality on meta-regression (*P* = 0.02, [**Figure 2**](#fig2){ref-type="fig"} and **[Supplemental Tables](#sup1){ref-type="supplementary-material"}** 3 and **[4](#sup1){ref-type="supplementary-material"}**).

![Meta-regression of the year follow-up ended and all-cause mortality. Each study (*n* = 149) is represented by a circle and size demonstrates weighting of each study, where larger circles indicate more patient-years of follow-up. The line of best fit shows the change in mortality rate for each year (β: −0.002; 95% CI: −0.003, −0.0003), *P* value = 0.018.](nqz110fig2){#fig2}

Enteral autonomy {#sec3-3}
----------------

Enteral autonomy was achieved in 54% (3653/6747) of children at a rate of 20.1% per y (95% CI: 17.6, 22.6, **[Supplemental Figure 6](#sup1){ref-type="supplementary-material"}**). Enteral autonomy was strongly correlated with small bowel length ([**Figure 3**](#fig3){ref-type="fig"} and **[Supplemental Table 5](#sup1){ref-type="supplementary-material"}**) and NEC as an etiology was associated with higher rates of enteral autonomy on meta-regression (**[Supplemental Figure 7](#sup1){ref-type="supplementary-material"}**), which has been reported previously (**[Supplemental Figure 8](#sup1){ref-type="supplementary-material"}**). However, presence of the ileocecal valve was not associated with enteral autonomy. The 7 cohorts with "ultra-short bowel syndrome" had lower rates of enteral autonomy but no other differences in clinical outcomes (**[Supplemental Table 6](#sup1){ref-type="supplementary-material"}**).

![Meta-regression between small bowel length and the proportion of patients reaching enteral autonomy. Each study (*n* = 71) is represented by a circle and size demonstrates weighting of each study, where larger circles indicate more patient-years of follow-up. The line of best fit shows the change in enteral autonomy rate for centimeter increase in small bowel length (β: 0.002; 95% CI: 0.001, 0.004), *P* value = 2.5 × 10^−4^.](nqz110fig3){#fig3}

Similar to all-cause mortality, there was evidence of improved rates of enteral autonomy in more recent cohorts ([Supplemental Table 4](#sup1){ref-type="supplementary-material"}) and when assessed by meta-regression (*P* = 0.03, [Supplemental Table 5](#sup1){ref-type="supplementary-material"}). Funnel plots for enteral autonomy and mortality were asymmetrical (**[Supplemental Figures 9](#sup1){ref-type="supplementary-material"}** and **[10](#sup1){ref-type="supplementary-material"}**).

Liver disease {#sec3-4}
-------------

IFALD affected 43.5% (2065/4746) of patients and was associated with sepsis and gestational age, but not with total duration of PN or bowel length. Meta-regression demonstrated strong positive correlations between IFALD and CRBSI (*P* = 1.7 × 10^−7^, [**Figure 4**](#fig4){ref-type="fig"} and **[Supplemental Table 7](#sup1){ref-type="supplementary-material"}**), as well as IFALD and NEC (*P* = 1.2 × 10^−5^, [Supplemental Table 7](#sup1){ref-type="supplementary-material"}). IFALD was negatively correlated with gestational age (*P* = 5.5 × 10^−4^, [Supplemental Table 7](#sup1){ref-type="supplementary-material"} and **[Supplemental Figure 11](#sup1){ref-type="supplementary-material"}**). Several studies had previously reported that total (or mean) durations of PN and bowel length were independent predictors of IFALD (**[Supplemental Figure 12](#sup1){ref-type="supplementary-material"}**), although we found no evidence for this.

![Meta-regression between the rate of CRBSI per 1000 catheter days and development of IFALD. Each study (*n* = 37) is represented by a circle and size demonstrates weighting of each study, where larger circles indicate more patient-years follow-up. The line of best fit shows the change in IFALD rate for each incidence of CRBSI per 1000 days (β: 0.02; 95% CI: 0.01, 0.03), *P* value = 1.7 × 10^−7^. CRBSI, catheter-related bloodstream infection; IFALD, intestinal failure--associated liver disease.](nqz110fig4){#fig4}

Neurodevelopment and other outcomes {#sec3-5}
-----------------------------------

Neurodevelopmental outcomes were described in 13/220 (6%) cohorts but were not suitable for meta-analysis. Normal development was reported in 29--100% of children; 80--90% of children were in mainstream schools. Some studies reported that children with moderate--severe developmental delay also had other comorbidities (e.g., extreme prematurity, cerebral abnormalities). One study that performed structured developmental assessments found both cognitive and motor impairment in \>50% at 2 y ([@bib25]).

Significant increases in both height and weight were achieved during the follow-up period (**[Supplemental Figure 13](#sup1){ref-type="supplementary-material"}**), although children remained below average and catch-up was less effective for height \[*z* score = −1.0 (95% CI: −1.1, −1.03)\] than weight \[*z* score = −0.88 (95% CI: −0.89, −0.86)\].

Despite recent reports of lower sepsis rates ([@bib26]), we were unable to find a difference between early and late cohorts.

Reporting and definitions {#sec3-6}
-------------------------

There was high variation in the reporting of baseline patient characteristics (**[Supplemental Table 8](#sup1){ref-type="supplementary-material"}**). Twenty-eight definitions of "intestinal failure" and 9 definitions of IFALD were used by included studies (**[Supplemental Table 9](#sup1){ref-type="supplementary-material"}**).

Discussion {#sec4}
==========

In this meta-analysis we have generated accurate rates for clinical outcomes and demonstrated that sepsis is the most important modifiable risk factor for morbidity and mortality. These results deepen our understanding of the condition in addition to providing useful baseline data for guideline development and counseling of parents.

We found a 5% annual mortality rate for children with IF, which was heavily driven by sepsis and liver disease, as had been found in individual cohorts ([@bib3], [@bib27]). Further analysis demonstrated that CRBSI was also strongly associated with IFALD, along with prematurity and NEC. This is consistent with the hypothesis that recurrent septic inflammation causes hepatic immune activation, which triggers progressive fibrosis, and that this is particularly harmful in the context of an immature liver ([@bib28]--[@bib31]).

Prevention of sepsis has long been recognized as a key outcome in the management of IF. Ethanol locks have also been shown to reduce the CRBSI rate by 81% ([@bib32]), and implementation of a multidisciplinary intestinal rehabilitation program can reduce sepsis and mortality rates ([@bib33]). However, we were unable to demonstrate improvement in sepsis rates in this analysis, which may reflect the broad nature of the review, including cohorts from small and large centers. Our data suggest that widespread adoption of established beneficial interventions could limit the morbidity and mortality associated with IFALD.

These results challenge the notion that duration of PN, small bowel length, or presence of ICV are causative for IFALD. Although long-term PN is necessary for the development of IFALD, it does not seem to be sufficient. Lauriti et al. had found PN duration to correlate with incidence of cholestasis; however, this study compared shorter PN durations, including \<30 days ([@bib14]). Cumulatively, these data suggest that the factors predictive of IFALD are distinct from those associated with achieving enteral autonomy.

Consistent with evidence from individual centers of improving mortality ([@bib11]), we found a trend of reducing mortality on meta-regression. We report lower mortality and higher enteral autonomy than found by Squires et al. ([@bib3]), which may reflect the shorter follow-up (26 mo) in their study. Improved neonatal care, development of surgical techniques, and use of fish oil--based lipid, among other interventions, are likely to have contributed to improved mortality. Similarly, the proportion of patients reaching enteral autonomy has improved with time. Enteral autonomy was strongly associated with small bowel length but not with presence of ICV. Though previous studies ([@bib15]) have found the ICV to be a key variable, in this meta-regression it was not associated with any clinical outcomes. Presence of ICV is also strongly correlated with presence of the colon, which may independently be beneficial for weaning of PN ([@bib34], [@bib35]). Our study also corroborates previous findings that NEC is positively associated with weaning from PN ([@bib15], [@bib36]). This result may reflect that other etiologies of short bowel syndrome (for example, gastroschisis or atresias) are associated with poorer enteral autonomy ([@bib36]). The mechanism for this is unclear but supports the concept that disease etiology impacts on the rehabilitation capacity in remaining bowel.

Our data also illustrate the overall burden of morbidity for these patients, including need for CVC replacement and frequency of venous thrombosis. Extensive venous thrombosis (with loss of central access) is an indication for intestinal transplant. However, many of these thromboses are subclinical ([@bib37]), and therefore it is not yet established whether active surveillance or prophylaxis would be of benefit ([@bib38]).

Limitations of the study {#sec4-1}
------------------------

Neurodevelopment is a key outcome for (often expremature) children with any chronic disease. So et al. have recently reported 2 structured assessments of neurodevelopment that reveal significant deficits even into childhood ([@bib25], [@bib39]). Overall, there was limited reporting of developmental outcomes and insufficient evidence to draw firm conclusions, highlighting the need for further work in this area.

As a cohort meta-analysis, it was not possible to follow individuals through their disease course. If individual patient-level data had been available, it would have facilitated more detailed analysis of patients' disease course by disease etiology. A further risk of cohort meta-analyses is the potential for double-counting of individual patients by their inclusion in 2 studies. We attempted to limit this by excluding data from overlapping cohorts at each center but were unable to verify whether any patients were duplicated in our analyses.

This meta-analysis and meta-regression was also limited by underreporting of baseline characteristics, such as ethnicity and sex, and a lack of individual patient-level data, which reduced the power for exploring associations. There were also limited data from outside North America and Europe.

Finally, there was evidence of bias on funnel plots. This may be due to: *1*) analysis of mortality ratios, which limits the lower bound as zero; *2*) study heterogeneity; or *3*) publication bias, as similar bias was observed for enteral autonomy.

Conclusion {#sec4-2}
----------

Sepsis and IFALD are the 2 key variables most strongly associated with mortality in pediatric IF, although overall mortality has improved. The associations of IFALD are distinct from the factors predicting enteral autonomy. The neurodevelopmental outcome of pediatric IF is unclear and requires further investigation.
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